Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

I am not a Healthcare Professional
Prescribing Information Tezspire®▼(tezepelumab)
Adverse Event Reporting
Safety Information

This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

AstraZeneca-logo
  • Our Medicines
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
        • WAINZUA®▼(eplontersen)
      • Chronic Kidney Disease (CKD)
        • FORXIGA® (dapagliflozin)
      • Heart Failure
        • FORXIGA® (dapagliflozin)
      • Hyperkalaemia
        • LOKELMA® (sodium zirconium cyclosilicate)
      • Type 2 Diabetes (T2D)
        • FORXIGA® (dapagliflozin)
    • Oncology
      • Breast Cancer
        • LYNPARZA® (olaparib)
        • TRUQAP®▼(capivasertib)
      • Bladder Cancer
        • IMFINZI® (durvalumab)
      • Endometrial Cancer
        • IMFINZI® (durvalumab)
        • LYNPARZA® (olaparib)
      • Gastrointestinal Cancer
        • IMFINZI® (durvalumab)
        • IMJUDO®▼(tremelimumab)
      • Lung Cancer
        • IMFINZI® (durvalumab)
        • TAGRISSO® (osimertinib)
      • Ovarian Cancer
        • LYNPARZA® (olaparib)
      • Prostate Cancer
        • LYNPARZA® (olaparib)
        • ZOLADEX® (goserelin)
    • Respiratory
      • Asthma
        • TEZSPIRE®▼ (tezepelumab)
        • SYMBICORT® (budesonide/formoterol)
      • Chronic Obstructive Pulmonary Disease(COPD)
        • TRIXEO AEROSPHERE® (formoterol fumarate dihydrate/glycopyrronium/budesonide)
        • BEVESPI® (glycopyrronium/formoterol fumarate dihydrate)
    • Vaccines
      • Flu
        • FLUENZ® nasal spray suspension (influenza vaccine, live attenuated, nasal)
  • Therapy Areas
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
      • Chronic Kidney Disease (CKD)
      • Heart Failure
      • Hyperkalaemia
      • Type 2 Diabetes (T2D)
    • Oncology
      • Breast Cancer
      • Bladder Cancer
      • Endometrial Cancer
      • Gastrointestinal Cancer
      • Lung Cancer
      • Ovarian Cancer
      • Prostate Cancer
    • Respiratory
      • Asthma
      • Chronic Obstructive Pulmonary Disease(COPD)
    • Vaccines
      • Flu
  • About us
    • AZ Commitment
  • Contact us
  • AstraZeneca UK
  • Tezspire
  • Video library
  • The mode of action (moa) of Tezspire
  • Welcome to Tezspire
  • CRSwNP
  • How it works
  • Efficacy
    • Overview
    • Study Design
    • Exacerbation Data
    • Lung Function
    • Quality of Life
  • Patient Profiles
  • Safety
  • Dosing
  • Resources
    • Resources
    • Video Library
The mode of action (moa) of Tezspire

< Back to video library

Tezspire Mode of Action (MoA) in Severe CRSwNP

TEZSPIRE is the first and only biologic to target TSLP to address epithelial-driven inflammation. It inhibits multiple downstream pathways responsible for various clinical manifestations in the upper and lower airway.1-5

 

  1. Tezspire. Summary of Product Characteristics
  2. Menzies-Gow A, et al. Respir Res 2020;21(1):268
  3. Gauvreau G.M., et al. Expert Opin Ther Targets 2020;24(8):777-792
  4. Bognasco D, Int J Mol Sci. 2024;25(11):5972.
  5. Panettieri R Jr, et al J Asthma Allergy 2024:17;219–236

 

GB-75629 | July 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

Connessiallasalute.it

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Terms of use

Privacy Policy

Cookie Policy

Contact Us

LinkedIn

Twitter

©2024 AstraZeneca. GB-78067 | DOP: July 2026